Patents by Inventor Ki-Yoon Kim
Ki-Yoon Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240152056Abstract: The inventive concept provides a substrate treating method. The substrate treating method includes supplying a liquid to a substrate; and heating the substrate after the supplying the liquid, and wherein the supplying the liquid includes: supplying a first liquid to the substrate; and supplying a second liquid which is different from the first liquid to a substrate to which the first liquid is supplied, and wherein the second liquid is supplied as a test to the substrate and a contact angle between the second liquid which is supplied and the substrate is measured to determine a degree of hydrophilization of the substrate, and a supply mechanism of the second liquid supplied to the substrate is determined based on the degree of hydrophilization of the substrate which is determined, before the supplying the second liquid is performed.Type: ApplicationFiled: November 6, 2023Publication date: May 9, 2024Applicant: SEMES CO., LTD.Inventors: Sang Gun LEE, Ki Hoon CHOI, Hyun YOON, Seung Un OH, Jin Yeong SUNG, Jang Jin LEE, Tae Shin KIM
-
Patent number: 11959193Abstract: Disclosed are a spinning dope for an aramid and carbon-nanotube composite fiber and a method of manufacturing an aramid and carbon-nanotube composite fiber using the same.Type: GrantFiled: March 22, 2022Date of Patent: April 16, 2024Assignee: Korea Institute of Science and TechnologyInventors: Dae Yoon Kim, Ki Hyun Ryu, Bon Cheol Ku, Jun Yeon Hwang, Nam Dong Kim, Dong Ju Lee, Seo Gyun Kim
-
Publication number: 20240118607Abstract: The inventive concept provides a substrate treating method. The substrate treating method includes pre-treating a substrate by cleaning the substrate; etching the substrate by supplying an etchant and heating a substrate supplied with the etchant; and post-treating the substrate after the etching the substrate, and wherein the pre-treating the substrate, the etching the substrate, and the post-treating the substrate are each performed in different chambers, a substrate on which the pre-treating the substrate is completed is transferred in a dry state to a chamber at which the etching the substrate is performed, and a substrate on which the etching the substrate is completed is transferred in a wetted state with a liquid to a chamber at which the post-treating the substrate is performed.Type: ApplicationFiled: March 14, 2023Publication date: April 11, 2024Applicant: SEMES CO.,LTD.Inventors: Hyun YOON, Ki Hoon CHOI, Seung Un OH, Young Ho PARK, Sang Hyeon RYU, Tae Hee KIM, Sang Gun LEE
-
Patent number: 11891604Abstract: The present invention relates to use of miR-18b for prevention, treatment, or diagnosis of muscle diseases or neuromuscular diseases, and specifically it was confirmed that, in a muscle disease by gene mutations model, gene mutations reduce miR-18b expression, cause dysregulation of miR-18b signaling pathways, and thus induce calcium signaling, cell differentiation inhibition, and apoptosis. Therefore, miR-18b of the present invention may be used as a target factor for diagnosing and treating muscle diseases caused by gene mutations such as ALS and DMD.Type: GrantFiled: December 17, 2021Date of Patent: February 6, 2024Assignee: CURAMYS CO., LTD.Inventors: Jung-Joon Sung, Ki Yoon Kim
-
Patent number: 11850288Abstract: A gene and cell therapy using a cell fusion technology is proposed. Cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.Type: GrantFiled: June 30, 2020Date of Patent: December 26, 2023Assignee: CURAMYS INC.Inventors: Jung-Joon Sung, Seung-Yong Seong, Hee-Woo Lee, Ki Yoon Kim
-
Publication number: 20220186220Abstract: The present invention relates to use of miR-18b for prevention, treatment, or diagnosis of muscle diseases or neuromuscular diseases, and specifically it was confirmed that, in a muscle disease by gene mutations model, gene mutations reduce miR-18b expression, cause dysregulation of miR-18b signaling pathways, and thus induce calcium signaling, cell differentiation inhibition, and apoptosis. Therefore, miR-18b of the present invention may be used as a target factor for diagnosing and treating muscle diseases caused by gene mutations such as ALS and DMD.Type: ApplicationFiled: December 17, 2021Publication date: June 16, 2022Inventors: Jung-Joon SUNG, Ki Yoon KIM
-
Patent number: 11286484Abstract: The present invention relates to use of miR-18b for prevention, treatment, or diagnosis of muscle diseases or neuromuscular diseases, and specifically it was confirmed that, in a muscle disease by gene mutations model, gene mutations reduce miR-18b expression, cause dysregulation of miR-18b signaling pathways, and thus induce calcium signaling, cell differentiation inhibition, and apoptosis. Therefore, miR-18b of the present invention may be used as a target factor for diagnosing and treating muscle diseases caused by gene mutations such as ALS and DMD.Type: GrantFiled: February 14, 2020Date of Patent: March 29, 2022Assignee: CURAMYS CO., LTD.Inventors: Jung-Joon Sung, Ki Yoon Kim
-
Publication number: 20210322570Abstract: The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.Type: ApplicationFiled: June 25, 2021Publication date: October 21, 2021Inventors: Jung-Joon SUNG, Seung-Yong SEONG, Hee-Woo LEE, Ki Yoon KIM
-
Patent number: 11077207Abstract: The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.Type: GrantFiled: January 17, 2018Date of Patent: August 3, 2021Assignee: CURAMYS INC.Inventors: Jung-Joon Sung, Seung-Yong Seong, Hee-Woo Lee, Ki Yoon Kim
-
Publication number: 20200323997Abstract: A gene and cell therapy using a cell fusion technology is proposed. Cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.Type: ApplicationFiled: June 30, 2020Publication date: October 15, 2020Inventors: Jung-Joon SUNG, Seung-Yong SEONG, Hee-Woo LEE, Ki Yoon KIM
-
Publication number: 20200277603Abstract: The present invention relates to use of miR-18b for prevention, treatment, or diagnosis of muscle diseases or neuromuscular diseases, and specifically it was confirmed that, in a muscle disease by gene mutations model, gene mutations reduce miR-18b expression, cause dysregulation of miR-18b signaling pathways, and thus induce calcium signaling, cell differentiation inhibition, and apoptosis. Therefore, miR-18b of the present invention may be used as a target factor for diagnosing and treating muscle diseases caused by gene mutations such as ALS and DMD.Type: ApplicationFiled: February 14, 2020Publication date: September 3, 2020Inventors: Jung-Joon SUNG, Ki Yoon KIM
-
Publication number: 20180193487Abstract: The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.Type: ApplicationFiled: January 17, 2018Publication date: July 12, 2018Inventors: Jung-Joon SUNG, Seung-Yong SEONG, Hee-Woo LEE, Ki Yoon Kim
-
Patent number: 9534040Abstract: Provided is an antiviral agent against animal viruses. The antiviral agent contains a protein or a nucleic acid sequence encoding the protein, as an active ingredient, the protein having binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself. Also provided is an antiviral animal cell containing the protein according to the present invention, or the nucleic acid sequence encoding the protein. The antiviral agent and antiviral animal cell exhibit advantageous effects in that they selectively degrade foreign nucleic acid chains invaded in an animal cell and have no cytotoxicity to the animal cell, thus causing no death of the animal cell.Type: GrantFiled: August 6, 2014Date of Patent: January 3, 2017Assignees: Sungkyunkwan University Foundation for Corporate Collaboration, Ajou University Industry-Academic Cooperation Foundation, Invitroplant Co., Ltd., Ministry of Agriculture Food and Rural Affairs Animal and Plant Quarantine AgencyInventors: Suk-Chan Lee, Yong-Sung Kim, Myung-Hee Kwon, Tai-Hyun Kim, Jeong-Sun Kim, Gun-Sup Lee, Hye-Kyung Shim, Eul-Yong Park, Yu-Chul Chung, Ki-Yoon Kim, Yi-Jung Jung, Woo-Ram Lee, Young-Rim Kim, Jong-Nam Sohn, Seung-Hyun Lee, Jae Young Song, Eun Jin Choi
-
Publication number: 20160083455Abstract: Disclosed herein is an antiviral agent against animal viruses. The antiviral agent contains a protein or a nucleic acid sequence encoding the protein, as an active ingredient, the protein having binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself. Disclosed herein is further an antiviral animal cell containing the protein according to the present invention, or the nucleic acid sequence encoding the protein. The antiviral agent and antiviral animal cell exhibit advantageous effects in that they selectively degrade foreign nucleic acid chains invaded in an animal cell and have no cytotoxicity to the animal cell, thus causing no death of the animal cell.Type: ApplicationFiled: August 6, 2014Publication date: March 24, 2016Inventors: Suk-Chan Lee, Yong-Sung Kim, Myung-Hee Kwon, Tai-Hyun Kim, Jeong-Sun Kim, Gun-Sup Lee, Hye-Kyung Shim, Eul-Yong Park, Yu-Chul Jung, Ki-Yoon Kim, Yi-Jung Jung, Woo-Ram Lee, Young-Rim Kim, Jong-Nam Sohn, Seung-Hyun Lee, Jae Young Song, Eun Jin Choi
-
Patent number: 8400174Abstract: A method of correcting a position of a prober, the method including obtaining a first image of a pad, the pad having a predetermined reference contact position, contacting the prober to the pad after obtaining the first image of the pad, obtaining a second image of the pad after contacting the prober to the pad, determining an actual contact position of an actual contact mark on the pad, the actual contact mark being produced by the contacting of the prober to the pad, comparing the second image to the first image to obtain an offset data, the offset data relating the actual contact position to the reference contact position, and correcting the position of the prober by aligning the actual contact position with the reference contact position based on the offset data.Type: GrantFiled: February 2, 2010Date of Patent: March 19, 2013Assignee: Samsung Electronics Co., Ltd.Inventors: Seung-Yong Oh, Byoung Joo Kim, Dae-Gab Chi, Ki-Yoon Kim
-
Publication number: 20110306641Abstract: The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing same, a pharmaceutical composition for prevention and treatment of osteoporosis including same, applications of same for preparing the therapeutic agent of osteoporosis prevention and treatment, and a method for prevention and treatment of osteoporosis using same. The 2,6-substituted-3-nitropyridine derivative compound of the present invention effectively increases osteoblast activity and also inhibits the formation of osteoclasts, so that it may be usefully used for the prevention and treatment of osteoporosis.Type: ApplicationFiled: December 4, 2009Publication date: December 15, 2011Inventors: Jei Man Ryu, Jin Soo Lee, Whui Jung Park, Yun Ha Hwang, Ki_Yoon Kim
-
Publication number: 20110306606Abstract: The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing the same, and a pharmaceutical composition including the same for prevention and treatment of osteoporosis. The 2,6-substituted-3-nitropyridine derivative compound of the present invention increases osteoblast activity and effectively inhibits the differentiation of osteoclasts, and thus can be usefully used for the prevention and treatment of osteoporosis.Type: ApplicationFiled: December 4, 2009Publication date: December 15, 2011Inventors: Jei Man Ryu, Jin Soo Lee, Whui Jung Park, Yun Ha Hwang, Ki Yoon Kim
-
Publication number: 20110201104Abstract: Disclosed herein is an antiviral agent against animal viruses. The antiviral agent contains a protein or a nucleic acid sequence encoding the protein, as an active ingredient, the protein having binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself. Disclosed herein is further an antiviral animal cell containing the protein according to the present invention, or the nucleic acid sequence encoding the protein. The antiviral agent and antiviral animal cell exhibit advantageous effects in that they selectively degrade foreign nucleic acid chains invaded in an animal cell and have no cytotoxicity to the animal cell, thus causing no death of the animal cell.Type: ApplicationFiled: September 18, 2007Publication date: August 18, 2011Applicants: Sungkyunkwan University Foundaton for Corporate Collaboration, Ajou University Industry-Academic Cooperation Foundation, Invitroplant Co., Ltd.Inventors: Suk-Chan Lee, Yong-Sung Kim, Myung-Hee Kwon, Tai-Hyun Kim, Jeong-Sun Kim, Gun-Sup Lee, Hye-Kyung Shim, Eul-Yong Park, Yu-Chul Jung, Ki-Yoon Kim, Yi-Jung Jung, Woo-Ram Lee, Young-Rim Kim, Jong-Nam Sohn, Seung-Hyun Lee
-
Publication number: 20100249402Abstract: The present invention relates to novel benzamidine derivatives, a process for the preparation thereof and a pharmaceutical composition for preventing or treating osteoporosis comprising the same. The benzamidine derivatives of the present invention effectively inhibit osteoclast differentiation at an extremely low concentration, and thus can be advantageously used for the prevention and treatment of osteoporosis.Type: ApplicationFiled: July 28, 2008Publication date: September 30, 2010Applicant: DONG WHA PHARMACEUTICAL CO. LTD.Inventors: Jei Man Ryu, Jin Soo Lee, Young Goo Jin, Jae Hoon Park, Bo Kyung Kim, Dae Yeon Won, Yun-Ha Hwang, Ki Yoon Kim, Sae Kwang Ku
-
Publication number: 20100194418Abstract: A method of correcting a position of a prober, the method including obtaining a first image of a pad, the pad having a predetermined reference contact position, contacting the prober to the pad after obtaining the first image of the pad, obtaining a second image of the pad after contacting the prober to the pad, determining an actual contact position of an actual contact mark on the pad, the actual contact mark being produced by the contacting of the prober to the pad, comparing the second image to the first image to obtain an offset data, the offset data relating the actual contact position to the reference contact position, and correcting the position of the prober by aligning the actual contact position with the reference contact position based on the offset data.Type: ApplicationFiled: February 2, 2010Publication date: August 5, 2010Inventors: Seung-Yong Oh, Byoung Joo Kim, Dae-Gab Chi, Ki-Yoon Kim